Arcus Biosciences, Inc.
RCUS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $258 | $117 | $112 | $383 |
| % Growth | 120.5% | 4.5% | -70.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $258 | $117 | $112 | $383 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $448 | $340 | $288 | $257 |
| G&A Expenses | $120 | $117 | $104 | $72 |
| SG&A Expenses | $120 | $117 | $104 | $72 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $20 | $0 | $0 | $0 |
| Operating Expenses | $588 | $457 | $392 | $329 |
| Operating Income | -$330 | -$340 | -$280 | $54 |
| % Margin | -127.9% | -290.6% | -250% | 14.1% |
| Other Income/Exp. Net | $47 | $39 | $14 | $1 |
| Pre-Tax Income | -$283 | -$301 | -$266 | $55 |
| Tax Expense | $1 | $6 | $1 | $2 |
| Net Income | -$283 | -$307 | -$267 | $53 |
| % Margin | -109.7% | -262.4% | -238.4% | 13.8% |
| EPS | -3.14 | -4.15 | -3.71 | 0.76 |
| % Growth | 24.3% | -11.9% | -588.2% | – |
| EPS Diluted | -3.14 | -4.15 | -3.71 | 0.71 |
| Weighted Avg Shares Out | 90 | 74 | 72 | 69 |
| Weighted Avg Shares Out Dil | 90 | 74 | 72 | 74 |
| Supplemental Information | – | – | – | – |
| Interest Income | $52 | $41 | $16 | $1 |
| Interest Expense | $4 | $2 | $2 | $0 |
| Depreciation & Amortization | $10 | $8 | $6 | $4 |
| EBITDA | -$269 | -$291 | -$258 | $59 |
| % Margin | -104.3% | -248.7% | -230.4% | 15.4% |